Lyell Immunopharma (NasdaqGS:LYEL) Earnings Call Presentation

Lyell Strengthens Next-Generation CAR T-Cell Pipeline with Novel GCC-Targeted Product Candidate for Metastatic Colorectal Cancer Lyell Immunopharma November 10, 2025 Forward Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Lyell Immunopharma, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). All such written or oral statements made in this present ...